Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TIMP3 | P35625 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.62 |
| ▸ | RECQL | P46063 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | HPSE | Q9Y251 | 4/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.56 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.56 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18211298 | 0.91 | TIMP3 (0.64) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL6561310 | 0.87 | TIMP3 (0.62) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL11593603 | 0.87 | TIMP3 (0.68) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL17067860 | 0.86 | TIMP3 (0.64) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL18136599 | 0.86 | TIMP3 (0.93) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL24621483 | 0.85 | TIMP3 (0.72) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL3297268 | 0.85 | TIMP3 (0.66) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL375680 | 0.84 | TIMP3 (0.75) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL3300014 | 0.84 | HSD17B10 (0.74) | TIMP3HSD17B10RECQLKMT2ATDP1 | |
| SCHEMBL18211299 | 0.84 | TIMP3 (0.54) | TIMP3HSD17B10RECQLKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264043-B1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | TIMP3 1176/4885HSD17B10 3651/4885RECQL 4815/4885 |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | BSG, SELE, SELL | TIMP3 1643/4885HSD17B10 4424/4885RECQL 4379/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | TIMP3 1176/4885HSD17B10 3651/4885RECQL 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.